Share your videos with the world

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave. Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease. To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy

Presented here are few of the products which Vertex Product Development has designed, engineered and developed from conception to production for the Consumer, Commercial, Industrial and Medical industries.

Designing without 3D -CAD? That was yesterday. The calculation and simulation of computer models are now standard for even the smallest engineering firms. Meanwhile, the next stage of development has begun. Now the physical properties of various materials, the reaction of a module to certain influences, as well as the functioning of the entire system are also virtually modeled.

The Koga Ryu Ninjutsu system also has 5 elements, the students of Sensei Titus Mathijn Jansen are demonstrating the first 2 techniques of the